| Autor: |
Naruemit Sayabovorn, Pochamana Phisalprapa, Weerachai Srivanichakorn, Thanet Chaisathaphol, Chaiwat Washirasaksiri, Tullaya Sitasuwan, Rungsima Tinmanee, Chayanis Kositamongkol, Pongpol Nimitpunya, Euarat Mepramoon, Pinyapat Ariyakunaphan, Diana Woradetsittichai, Methee Chayakulkeeree, Pakpoom Phoompoung, Korapat Mayurasakorn, Nitat Sookrung, Anchalee Tungtrongchitr, Rungsima Wanitphakdeedecha, Saipin Muangman, Sansnee Senawong, Watip Tangjittipokin, Gornmigar Sanpawitayakul, Cherdchai Nopmaneejumruslers, Visit Vamvanij, Chonticha Auesomwang |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Tropical Medicine and Infectious Disease, Vol 8, Iss 4, p 185 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2414-6366 |
| DOI: |
10.3390/tropicalmed8040185 |
| Popis: |
The dynamics of humoral immune responses of patients after SARS-CoV-2 infection is unclear. This study prospectively observed changes in anti-receptor binding domain immunoglobulin G (anti-RBD IgG) and neutralizing antibodies against the Wuhan and Delta strains at 1, 3, and 6 months postinfection between October 2021 and May 2022. Demographic data, clinical characteristics, baseline parameters, and blood samples of participants were collected. Of 5059 SARS-CoV-2 infected adult patients, only 600 underwent assessment at least once between 3 and 6 months after symptom onset. Patients were categorized as immunocompetent (n = 566), immunocompromised (n = 14), or reinfected (n = 20). A booster dose of a COVID-19 vaccine was strongly associated with maintained or increased COVID-19 antibody levels. The booster dose was also more strongly associated with antibody responses than the primary vaccination series. Among patients receiving a booster dose of a mRNA vaccine or a heterologous regimen, antibody levels remained steady or even increased for 3 to 6 months after symptom onset compared with inactivated or viral vector vaccines. There was a strong correlation between anti-RBD IgG and neutralizing antibodies against the Delta variant. This study is relevant to resource-limited countries for administering COVID-19 vaccines 3 to 6 months after infection. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
